HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
HC Wainwright & Co. 维持买入评级,将目标股价调整为$57(进行1-20股票回拨)rigel pharmaceuticals
HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy, adjusts target to $57 from $15 (1-20 Reverse Stock Split).
HC Wainwright & Co. 分析师Joseph Pantginis维持Rigel Pharmaceuticals (纳斯达克:rigel pharmaceuticals)的买入评级,将目标价从15美元调整至57美元(1-20股票拆分)。